Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB04 vs EU-sourced Enbrel in Moderate to Severe Rheumatoid Arthritis
2024-510826-16-00Phase 3Completed
- Sponsor
- mAbxience
- Start
- Aug 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of etanercept in rheumatoid arthritis (RA) (2 arms), sponsored by mAbxience. Primary endpoint: ACR20 response rate at Week 24. Started Aug 2024; status: completed.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-510826-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510826-16-00.